AML
News
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
News
AFib risk with cancer drugs underestimated
Many cancer therapies increase the risk of atrial fibrillation, but this is underreported in clinical trials.
News
Venetoclax shows promise for r/r hairy cell leukemia
Italian study suggests benefits of administering venetoclax for patients with r/r cases of hairy cell leukemia, a rare blood cancer,
News
Transplant vs. chemo: Similar AML survival rates
New study showed similar survival rates among AML patients treated solely with consolidation chemotherapy and those who received allogenic HCT.
News
Drug combo holds promise of better AML outcomes
Study suggests that the venetoclax-gilteritinib drug combination “potentially improves response frequency and depth.”
News
Pivotal trials in blood cancers don’t mirror patient populations
“The results from this study should lead to questions about the generalizability of drug safety and efficacy in populations we serve as medical...
News
AML’s seasonal peak suggests viral or environmental etiology
“The environmental triggers involved could be radiation, pollution, allergens, or infectious agents like viruses.”
News
Evidence still lacking that vitamins prevent CVD, cancer: USPSTF
In its final recommendation statement on the subject, the task force does, however, recommend against use of vitamin E and beta-carotene.
Conference Coverage
‘Extremely exciting’ study results guide MM treatment options
New trial data help inform the tailoring of effective treatment approaches for patients with newly diagnosed multiple myeloma (MM).
News
Clozapine and cancer risk in schizophrenia patients: New data
The clozapine-related risk increase was specific to hematological malignancies only.
